Business Context and Reporting Period
Company: Protara Therapeutics, Inc. (TARA)
Filing Type: Form 8-K (Current Report)
Date: November 19, 2025
Context: The filing discloses the release of interim clinical data from the Phase 2 STARBORN-1 trial for TARA-002, an investigational cell-based therapy for pediatric patients with Lymphatic Malformations (LMs). The data was presented via an investor presentation and press release in connection with a conference call.
Key Financial Metrics
This Form 8-K is a disclosure of clinical trial results and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Clinical Results
The primary material event is the announcement of interim results from the STARBORN-1 trial as of the November 12, 2025 data cutoff:
- Study Population: 12 patients enrolled and received more than one dose of TARA-002.
- Efficacy (Clinical Success):
- 7 out of 8 evaluable patients (87.5%) achieved clinical success (defined as complete or substantial response) with one or two doses.
- 80% (8/10) of patients who completed treatment achieved clinical success.
- 100% (8/8) of patients who completed the eight-week response assessment achieved clinical success.
- 83% (5/6) of macrocystic patients achieved a complete response; the remaining macrocystic patient achieved a substantial response.
- The single mixed-cystic patient achieved a complete response.
- Long-term Data: Two patients reached the 32-week post-treatment assessment and remain disease-free.
- Safety Profile: The majority of adverse events (AEs) were mild to moderate. No serious AEs were reported. The most common AEs were swelling and fatigue. One patient discontinued treatment due to a Grade 2 AE of fatigue.
- Notable Case: One patient with a 1,739 ml macrocystic LM required all four doses to achieve a complete response. Another patient deemed a complete response was later diagnosed with a ranula (a different cyst type).
Guidance, Outlook, and Risks
Outlook: Management highlighted the potential of intracystic injection of TARA-002 based on the interim data. The filing includes standard forward-looking statements regarding future development plans, FDA interactions, and financial position.
Risks and Contingencies: The filing explicitly warns that actual results may differ materially from expectations due to risks including:
- Uncertainty in clinical trial initiation, completion, and timing.
- Regulatory filing timelines and FDA interactions.
- Ability to obtain sufficient financing for strategic plans.
- Market volatility impacting cash reserves.
- General economic, industry, and competitive landscape changes.
Investor Verification Checklist
- Verify the full text of the Press Release (Exhibit 99.2) and Investor Presentation (Exhibit 99.1) for detailed statistical tables and methodology.
- Confirm the specific definitions of "complete response" and "substantial response" used in the trial protocol.
- Review the company's most recent 10-Q or 10-K for current cash runway and burn rate, as this 8-K does not contain financial data.
- Monitor upcoming FDA communications regarding the STARBORN-1 trial design and potential regulatory pathways.
- Assess the impact of the one patient discontinuing due to fatigue on future dosing protocols.